SCHEMBL409135

SCHEMBL409135

O=c1ccn(-c2nccs2)c(=O)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.44
DDB1 Q16531 1/20 0.44
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.44
TDP1 Q9NUW8 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 2/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
G6PD P11413 1/20 0.39
PKM P14618 1/20 0.39
MPI P34949 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2A Q92830 1/20 0.39
KAT2B Q92831 1/20 0.39
SLC11A2 P49281 1/20 0.38
POLB P06746 1/20 0.36
APEX1 P27695 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25430620 0.77 SMN1; SMN2 (0.43) LMNAGLATDP1ALDH1A1GAA
SCHEMBL7830035 0.71 CRBN (0.55) CRBNDDB1L3MBTL1RXFP1
SCHEMBL5579491 0.70 LMNA (0.53) LMNAGLATDP1ALDH1A1GAA
SCHEMBL5820389 0.70 LMNA (0.42) LMNAGLATDP1ALDH1A1GAA
SCHEMBL28392243 0.70 CRBN (0.42) CRBNDDB1LMNAALDH1A1GAA
SCHEMBL28939023 0.70 LMNA (0.42) LMNAGLATDP1ALDH1A1GAA
SCHEMBL19692134 0.69 PARP1 (0.43) LMNAGLATDP1ALDH1A1GAA
SCHEMBL20688413 0.69 LMNA (0.41) LMNAGLATDP1ALDH1A1GAA
SCHEMBL4662853 0.68 CRBN (0.52) CRBNDDB1KDM4EPKM
SCHEMBL35210773 0.68 KDM4E (0.51) LMNAGLATDP1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080044425-A1 POLYPEPTIDES HAVING PHOSPHOLIPASE A2 ACTIVITY KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-02-21 US claimed
US-20080015165-A1 NOVEL POLYPEPTIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-17 US claimed
US-7291491-B2 Having poly-N-acetyllactosamine sugar chains synthesis-related activity; use in antiinflammation, antiinfection, inhibition of cancer metastasis KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-11-06 US claimed
JP-3739785-B2 2006-01-25 JP claimed
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES FROEHLER BRIAN (US) 2004-12-30 US claimed
US-20040014089-A1 Polypeptides having phospholipase a2 activity KYOWA HAKKO KIRIN CO., LTD. (JP) 2004-01-22 US claimed
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines FROEHLER BRIAN (US) 2003-09-11 US claimed
US-20030166208-A1 Novel polypeptides KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-09-04 US claimed
EP-1329511-A1 POLYPEPTIDE HAVING PHOSPHOLIPASE A2 ACTIIVTY KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-07-23 EP claimed
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines ISIS PHARMACEUTICALS, INC. 2003-05-22 US claimed
EP-0637965-B1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES ISIS PHARMACEUTICALS INC (US) 2002-10-16 EP claimed
EP-1162269-A1 NOVEL POLYPEPTIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-12-12 EP claimed
EP-1103604-A1 NOVEL POLYPEPTIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-05-30 EP claimed
WO-1999052906-A1 SUBSTITUTED OXAZOLYLE AND THIAZOLYL URACIL HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-10-21 WO claimed
EP-0937775-A2 Beta 1,3-N-acetylglucosaminyltransferase, DNA encoding it and its use KYOWA HAKKO KOGYO CO., LTD. (JP) 1999-08-25 EP claimed
EP-0637965-A4 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. GILEAD SCIENCES INC (US) 1996-01-24 EP claimed
EP-0637965-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1995-02-15 EP claimed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO claimed
CN-114828890-A Treatment of diabetes with stem cell migration agent 比奥兹普科德公司 2022-07-29 CN disclosed
WO-1999052906-A1 SUBSTITUTED OXAZOLYLE AND THIAZOLYL URACIL HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 CRBN 2611/4885DDB1 150/4885LMNA 1678/4885
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES NUDT1, DHX15, DDX5 CRBN 2611/4885DDB1 150/4885LMNA 1678/4885
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 CRBN 2611/4885DDB1 150/4885LMNA 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.